A similar pattern is observed in NPC, where CCND1 inhibition enhances the sensitivity to cisplatin 41, 42, indicating that targeting CCND1 could serve as a potential therapeutic strategy for this malignancy. Here, CCND1 is linked to nasopharyngeal carcinoma.